Original endomorphin-1 analogues exhibit good analgesic effects

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Drug Discovery

Background:

• Endomorphin-1 (EM-1) is a potent endogenous opioid peptide.
• Developing stable and effective opioid analgesics remains a significant challenge.
• Modifications to EM-1 structure can potentially enhance its therapeutic profile.

Purpose of the Study:

• To synthesize novel endomorphin-1 analogues with improved pharmacological properties.
• To evaluate the receptor affinity, metabolic stability, and analgesic activity of these new compounds.
• To explore the potential of these analogues as drug candidates for pain management.

Main Methods:

• Chemical synthesis of endomorphin-1 analogues incorporating N-terminal guanidino modification, Phe4 chlorination, and D-Ala-Gly substitution at Pro2.
• Radioligand binding assays to determine μ- and δ-opioid receptor affinity.
• In vitro metabolic stability assays to measure peptide half-lives.
• In vivo tail-flick test in mice to assess analgesic efficacy.

Main Results:

• Analogue GAGPC exhibited 1.42-fold higher μ-opioid and 2.51-fold higher δ-opioid receptor affinity compared to EM-1.
• GAGPC demonstrated significantly enhanced metabolic stability with a half-life 53-fold longer than EM-1.
• In vivo studies showed GAGPC possesses superior analgesic activity, attributed to increased blood-brain barrier permeability via chloride modification.

Conclusions:

• The synthesized endomorphin-1 analogues, particularly GAGPC, represent a promising new class of compounds.
• GAGPC's enhanced receptor binding, metabolic stability, and central analgesic effects highlight its therapeutic potential.
• These findings suggest GAGPC could be a valuable drug candidate for developing novel analgesics.